1. Home
  2. PLUS vs IMCR Comparison

PLUS vs IMCR Comparison

Compare PLUS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ePlus inc.

PLUS

ePlus inc.

HOLD

Current Price

$91.71

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$36.59

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLUS
IMCR
Founded
1990
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
PLUS
IMCR
Price
$91.71
$36.59
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$67.00
AVG Volume (30 Days)
216.9K
338.1K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
1.09%
N/A
EPS Growth
14.25
N/A
EPS
4.60
N/A
Revenue
$2,285,906,000.00
$379,590,000.00
Revenue This Year
$14.37
$32.31
Revenue Next Year
$3.17
$10.50
P/E Ratio
$18.79
N/A
Revenue Growth
9.24
28.11
52 Week Low
$53.83
$23.15
52 Week High
$93.98
$40.72

Technical Indicators

Market Signals
Indicator
PLUS
IMCR
Relative Strength Index (RSI) 63.06 49.05
Support Level $88.49 $35.35
Resistance Level $93.98 $40.71
Average True Range (ATR) 2.71 1.82
MACD -0.23 -0.45
Stochastic Oscillator 71.86 22.55

Price Performance

Historical Comparison
PLUS
IMCR

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: